Important note: Information in this article was accurate in 2001. The state of the art may have changed since the publication date.
PRNewswire - December 17, 2001
"Drugs that prevent integration would be an invaluable addition to the anti-HIV drug arsenal," said Dr. Kornbluth, who is an Associate Professor of Medicine at the U.C. San Diego, and the V.A. San Diego Healthcare System.
"This new test will finally allow scientists to identify drugs that intercept HIV during the integration process and stop the virus in its tracks."
amfAR awarded Dr. Kornbluth some of his first funding for his research on HIV integration. "amfAR's funding was pivotal in the success of this project and I am grateful for the Foundation's foresight in recognizing the enormous potential of this project," said Dr. Kornbluth.
"amfAR's freedom and flexibility to respond quickly to emerging research opportunities allowed us to quickly recognize the importance of Dr. Kornbluth's work," said Dr. Jeffrey Laurence, amfAR's Senior Scientific Consultant, and Director of the Laboratory for AIDS Virus Research at Cornell University's Weill College of Medicine. "We are very pleased that he will be honored for his breakthrough discovery, which exemplifies amfAR's mission of investing in goal-oriented, cutting-edge science."
Dr. Kornbluth's work will be published this month in the Journal of Biological Chemistry. His research has received support from the National Institutes of Health, the University of California, and the U.S. Department of Veteran Affairs. In addition to Dr. Kornbluth, GlaxoSmithKline honored two other researchers for their groundbreaking work to develop new pharmaceutical strategies to fight AIDS.
amfAR is the nation's leading nonprofit organization dedicated to the support of AIDS research, prevention, treatment education, and the advocacy of sound AIDS-related public policy. Since 1985, amfAR has invested nearly $190 million in support for its programs and awarded grants to over 1,900 research teams worldwide.
Contact: Naomi Starkman, Director of Communications of amfAR, +1-212-806-1602 or +1-917-847-0181
SOURCE American Foundation for AIDS Research Web Site: http://www.amfar.org
011217
PR011226
Copyright © 2001 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.PRNewswire.com.
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .